Lilly’s rare pancreatic cancer target just gained FDA momentum, but olomorasib still faces its hardest test
Eli Lilly and Company has secured an expedited United States regulatory pathway for olomorasib in a rare, previously treated pancreatic cancer population. The designation increases FDA engagement around the programme, but the investigational therapy still needs a pancreatic cancer-specific evidence package capable of supporting approval.